Cerebral Malaria Clinical Trial
Official title:
Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria: a Randomized Clinical Trial
Cerebral malaria is the most lethal complication of P.falciparum infection with a mortality rate between 5 and 40%. Intravenous quinine remains the recommended treatment for cerebral malaria. However its administration is often not feasible due to lack of simple equipment or trained staff. When referral is not possible, a viable alternative is needed. The intrarectal route is of interest in children since it is painless and simple. Studies of the efficacy of intrarectal quinine in the treatment of cerebral malaria are limited. The study aims to establish the efficacy of intrarectal quinine in the treatment of childhood cerebral malaria.
Cerebral malaria is the most lethal complication of P.falciparum infection with a mortality
rate between 5 and 40%. Intravenous quinine remains the recommended treatment for cerebral
malaria. However its administration is often not feasible due to lack of simple equipment or
trained staff. When referral is not possible, a viable alternative is needed. The
intrarectal route is of interest in children since it is painless and simple. A few studies
in Francophone Africa have reported clinical efficacy and tolerance of intrarectal quinine.
Although the studies were randomized trials, they were not blinded and did not use the WHO
definition of cerebral malaria as selection criteria.
The current study aims to establish whether intrarectal quinine is as effective and as safe
as intravenous quinine in the treatment of childhood cerebral malaria.
To address the shortcomings of the Francophone African studies, the investigators have
designed a randomized, double blind placebo controlled clinical trial to include patients
who meet the WHO definition of cerebral malaria.
Hypothesis:
Intrarectal quinine (15mg/kg every 8 hours) given to children with cerebral malaria, will
lead to a shorter parasite clearance time (39.9 hours) than intravenous quinine (55.0
hours).
The investigators calculated a sample size of 54 patients in each group for 90% power and
95% confidence. In the calculation, the researchers assumed that the children receiving
intrarectal quinine would have a mean parasite clearance time of 39.9 (SD 24.3) hours and
those receiving intravenous quinine would have a mean parasite clearance time of 55.0(SD
24.3) hours (27.5% effect size), according to a study by Aceng, Byarugaba and Tumwine in the
same hospital.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01589289 -
Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC
|
Phase 3 | |
Unknown status |
NCT00697164 -
Randomized Trial of Erythropoietin During Cerebral Malaria
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT00113854 -
Mannitol as Adjunct Therapy for Childhood Cerebral Malaria
|
Phase 3 | |
Completed |
NCT01982812 -
A Dose-Escalation, Safety and Feasibility Study of Enteral LVT for Seizure Control in Pediatric CM
|
Phase 2 | |
Completed |
NCT01660672 -
Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria
|
Phase 1/Phase 2 |